The growing requirement to have organ transplants and tissue repair, along with insufficient donor organs, poses a serious issue in medical care, which drives the growth of the market.
3D bioprinting is fundamentally a rapid prototyping and additive production technology used to fabricate artificial implants or multifaceted tissue constructs via a layer-by-layer building process for patient-centric therapy. 3D bioprinting shares three basic concepts with usual 2D printing: a desktop printer, a print file, ink such as bioink consisting of biomaterials, bioactive components, and cells, and paper. The 3D structure with patient-centric design is then printed in a layer-by-layer deposition modeling process in the bio-printing phase. Cellular bioprinting technology directly deposits bioinks with viable cells to form a 3D living structure. 3D bioprinting directly employs living cells in the construct fabrication technology, together with the inherent advantages of 3D printing-driven rapid prototyping.
The global 3D bioprinting for tissue and organ regeneration market size was estimated at USD 2.84 billion in 2025 and is predicted to increase from USD 3.38 billion in 2026 to approximately USD 16.04 billion by 2035, expanding at a CAGR of 18.9% from 2026 to 2035.
In 2025, 49,064 organ transplants were performed nationwide in the U.S.
| Name of Organ | Quantity of Transplant |
| Kidney transplants | 27,573 |
| Liver transplants | 12,344 |
Recent advancements in three-dimensional (3D) bioprinting are an evolving production technology for fabricating artificial tissues and organs for transplantation and drug screening. bioprinting technologies used to fabricate constructs, including jetting-driven, extrusion-based, vat photopolymerization-based processes, and other evolving 3D bioprinting strategies. The different kinds of bioinks, cell sources, and the most recent uses of 3D bioprinting tissues and organs in transplantation and drug testing. 3D bioprinting stage, which has been designed and advanced to print live tissues and organs.
By technology, the extrusion-based bioprinting segment contributed the largest U.S. 3D bioprinting for tissue and organ regeneration market share of 42% in 2025. Extrusion-based printing with a single nozzle is the most widely applied technology for 3D bioprinting. Extrusion provides a simplified design and print technology, which makes it well-suited for labs with limited access to CAD software or starting out. Light-driven bioprinting technology is presently the standard choice for reproducing the minimum, most intricate structures of the patient's body.
By material type, the bioinks segment contributed the largest market share of 46%, as bioinks allow 3D bioprinting of tissue constructs for drug transplantation and screening; select suitable bioinks for particular tissue engineering. Bioinks solidify during or at the end of bioprinting to build the designed tissue-like shapes and architecture. Bioinks are the resources used to contain cells when bioprinting tissues.
By component, the 3D bioprinters segment held a significant share of 39% in the U.S. 3D bioprinting for tissue and organ regeneration market, as 3D bioprinters transform medicine by constructing living, customized tissue and organ structures with high accuracy, allowing patient-centric implants that remove rejection challenges. It could directly allow the creation of transplantable organs.
By application, the tissue engineering segment contributed the largest market share of 38%, with the benefits of 3D bioprinting over typical 3D printing, involving precise cell distribution, high-resolution cell deposition, scalability, and affordability. 3D bioprinting technology has developed as a flexible tool in tissue engineering and regenerative medicine to fabricate or pattern functional 3D bio-structures.
By end-user, the pharmaceutical & biotechnology companies segment captured 34% share in 2025. They are driving innovation by replacing animal trials with human-relevant tissue models. This sector is aggressively shifting toward precision medicine and advanced toxicology testing, making it one of the most lucrative segments across the medical additive manufacturing industry.
The four organizations in this market dominate the U.S. 3D bioprinting for tissue and organ regeneration market. Meanwhile, Organovo, a prominent player focusing on 3D bioprinting functional individual liver and kidney tissues for drug discovery. CollPlant Biotechnologies is known for its rhCollagen BioInk, which is used for printing tissue. Allevi offers accessible 3D bioprinters and bioinks, broadly used in research institutions. Prellis Biologics, Inc. mainly focuses on making fully vascularized human tissues and immune system organoids via high-speed.
By Technology
By Material Type
By Component
By Application
By Deployment Mode
By Cell Source
By End User
